Eurocine Vaccines publishes its interim report July 2021 – March 2022

Eurocine Vaccines AB (post) (“Eurocine vaccines) publishes the interim report for July 2021 for December 2022. Below is a summary of the report. The full report is available on Eurocine vaccines website (https://eurocine-vaccines.com/) and attached.

2022-01-01 – 2022-03-31 (third quarter)

• Earnings after tax for the quarter amounted to -5.6 Mkr (-4.6 Mkr)
• Revenue for the quarter was Tkr ​​0 (Tkr 75)
• Earnings per share for the quarter amounted to -0.397 kr (-0.582 kr)

2021-07-01 – 2022-03-31 (nine month period)

• The result after tax for the period amounts to -15.0 Mkr (-12.2 Mkr)
• Revenue for the period amounted to 0 Tkr (457 Tkr)
• Earnings per share for the period amount to -1,053 kr (-1,544 kr)

Highlights of the period

Eurocine vaccines entered into an agreement with Flerie Invest to secure the exercise of the TO 4 series warrants

In February 2022, Eurocine vaccines entered into an agreement to secure the redemption of the series TO 4 warrants with Flerie Invest for the exercise period which took place from 14 to March 28, 2022. The agreement relates to underwriting and underwriting commitments of around 61.4% of the issue volume.

Eurocine vaccines announced that Flerie Invest is going into custody

As part of the agreement to secure the redemption of the warrants in February, Flerie Invest entered into a blocking agreement for 100% of its stake, corresponding to 13% of the total share capital and votes of the company.

Eurocine vaccines announced subscription price for the exercise of the Series TO 4 Warrants

Eurocine vaccines announced that the subscription price for the Series TO 4 Warrants was SEK1.41 per share.

Eurocine vaccines announced result of the exercise of the option

In March 2022, Eurocine vaccines announces that approximately 84.5% of the TO 4 warrants have been exercised. Including the subscription and guarantee commitment of Flerie Invest, Eurocine vaccines received approximately 4.5 million Swedish crowns before issuance costs.

Highlights after period

Vaccines Announced Date of Conversion of Interim Shares

In April 2022, Eurocine vaccines announced that the conversion of the provisional shares into ordinary shares would take place on April 14, 2022.

CEO Hans Arwidsson

Our third quarter is now complete and, in addition to our continued efforts to initiate the clinical phase of our chlamydia vaccine candidate, we have also been focused on further developing our portfolio of vaccine candidates. The start of 2022 has meant intensive work, evaluating and negotiating additional vaccine candidates that I look forward to sharing with the market. The expansion of our portfolio of innovative vaccine candidates is a strong lever of value for the company, given the Eurocine vaccines extensive knowledge and experience in vaccine development, but perhaps particularly important to meet our society’s need for modern and effective vaccines.

Internationally as in Sweden, vaccines and vaccine developers are increasingly highlighted as important societal functions to ensure global public health – new vaccines are needed to keep pace with new and constantly changing pathogens and thus contribute to the health of future generations. We are proud to be part of this context and it motivates us every day in our development work.

During the quarter, we successfully completed the exercise of the warrant, and I would like to thank all those who chose to exercise their TO 4. Significant work is currently underway to ensure the quality of the various stages of the process of manufacturing for clinical trial. The capital will finance, among other things, this work. In total, approximately 84.5% of the TO 4 were subscribed and, in combination with the support of our main shareholder, Flerie Invest, we were able to reach 100% of the issue volume. This will fund near-future goals such as scale-up and manufacturing of the investigational product and the start of the toxicology study before the planned start of the clinical trial in the first half of 2023.

Building a vaccine portfolio takes time and requires a broad combination of skills and experience in vaccine development, vaccine markets, legal and business development, skills that the management team of Eurocine vaccines to have. These are the right skills to build a strong portfolio where we develop and refine multiple innovations into attractive candidates.

In addition to identifying, evaluating and negotiating other vaccine candidates, where we have recently focused on evaluation and negotiation, we are also working long-term to prepare vaccine companies who are our potential future partners. for the chlamydia vaccine candidate. Even though the vaccine market is relatively concentrated on a limited number of large global players, I am very pleased with the interest I am seeing, both in partnership conferences and in direct contacts within our large network.

As we approach the end of the fiscal year, I look back on a year of development in which we completed a number of important activities that resulted in a solid foundation for planning our next clinical trial with the candidate vaccine against chlamydia.

Finally, I would like to thank all the shareholders of Eurocine vaccines for your confidence. With the team, I expect continued success, both in the development of the chlamydia vaccine candidate and in the expansion of the vaccine portfolio.

Please follow us on upcoming activities, which will appear in our Scheduleand discover our latest presentation, Aktiedagen Stockholm on March 14.

Hans Arwidsson – VD, Eurocine Vaccines AB

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB
[email protected]

+46 70 634 0171

Eurocine vaccines is a development company in the very intense field of vaccines, bridging the gap between innovation and the market.

Through its portfolio strategy, innovative vaccine candidates have the opportunity to reach the market faster, while investors are offered risk diversification with significant future leverage. These candidates are then licensed to partners for commercialization.

The company has its own technology platform, Endocine(TM), which has been tested in four extensive clinical studies with over 400 subjects.

Listed at Stock marketXSAT, Eurocine vaccinesEUCI, operates today at the heart of the bio-scientific pole of Karolinska InstituteSolna, Sweden and has attracted several internationally renowned vaccine specialists to its Board of Directors.

https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-publishes-interim-report-for-july-2021—march-2022,c3571105

https://mb.cision.com/Main/11552/3571105/1582380.pdf

https://mb.cision.com/Public/11552/3571105/9681ff23e6daa0af.pdf

(c) Decision 2022. All rights reserved., sources Press Releases – English